4-[5-(4-fluorophenyl)-2-(2-methanesulfinyl-benzylsulfanyl)-1H-imidazol-4-yl]-pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[5-(4-fluorophenyl)-2-(2-methanesulfinyl-benzylsulfanyl)-1H-imidazol-4-yl]-pyridine
• 英文别名: 5-(4-fluorophenyl)-2-[2-(methylsulfinyl)-benzylthio]-4-(4-pyridinyl)-1H-imidazole；4-[4-(4-fluorophenyl)-2-[(2-methylsulfinylphenyl)methylsulfanyl]-1H-imidazol-5-yl]pyridine
• 化学式: C₂₂H₁₈FN₃OS₂
• 分子量: 423.535
• InChiKey: KRRCAAGRJZQAMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-chloromethyl-2-methanesulfinylbenzene 、 4-(4-fluorophenyl)-5-(pyridin-4-yl)-1,3-dihydro-imidazole-2-thione 以 乙醇 为溶剂， 以54%的产率得到4-[5-(4-fluorophenyl)-2-(2-methanesulfinyl-benzylsulfanyl)-1H-imidazol-4-yl]-pyridine
  参考文献：
  名称：

  From Imidazoles to Pyrimidines:  New Inhibitors of Cytokine Release

  摘要：

  On the basis of model imidazole inhibitors of cytokine release, a series of novel pyridinyl pyrimidine derivatives was prepared and tested on their ability to inhibit the release of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-beta) from peripheral blood mononuclear cells (PBMC) and human whole blood. In the pyrimidine series, structure-activity relationships (SARs) similar to those of the imidazole series were found, although generally pyrimidine compounds were less potent. Modification of the substituent at the 2 position of the pyrimidine led to the most active compound 14 which inhibited release of TNF-alpha (IC50 = 3.2 muM) and IL-1beta (IC50 = 2.3 muM) from PBMC as effectively as the model imidazole inhibitor ML 3163 (TNF-alpha, IC50 = 3.7 muM; IL-1beta, IC50 = 0-9 muM). Screening in an isolated enzyme assay revealed both imidazole and pyrimidine compounds as inhibitors of p38 MAP (mitogen-activated protein) kinase.

  DOI：

  10.1021/jm011098a

文献信息

• 2-arylalkylthio -imidazoles, 2-arylalkenyl -thio -imidazoles and 2-arylalkinyl -thio -imidazoles as anti -inflammatory substances and substances inhibiting the release of cytokine
  申请人：Merckle GmbH

  公开号：US06432988B1

  公开（公告）日：2002-08-13

  The invention relates to 4-heteroaryl-5-phenylimidazole derivatives having 2-arylalkylthio, 2-arylalkenylthio and 2-arylalkynylthio substitution, of the general formula I: in which Ar is a phenyl radical, Het is a hetero aromatic radical, A is an alkylene chain, R1 is an alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamido or alkylcarbonyl group and R2 is an alkyl, hydroxyl, alkoxy, alkoxycarbonyl, sulfonamido, carboxyl, nitro or aminocarbonyl group or a halogen atom. n can be 1 or 2 and m is 0 to 2. The compounds according to the invention show antiinflammatory activity.

  该发明涉及具有2-芳基烷硫基，2-芳基烯基硫基和2-芳基炔基硫基取代的4-杂环芳基-5-苯基咪唑衍生物，其一般式为I： 其中Ar是苯基基团，Het是杂环芳基基团，A是烷基链，R1是烷硫基，烷砜基，烷砜基，磺胺基或烷基羰基基团，R2是烷基，羟基，烷氧基，烷氧羰基，磺胺基，羧基，硝基或氨基羰基基团或卤原子。n可以是1或2，m为0至2。根据该发明的化合物表现出抗炎活性。
• 2-Thio-substituted imidazole derivatives and their use in pharmaceutics
  申请人：Laufer Stefan

  公开号：US20060235054A1

  公开（公告）日：2006-10-19

  The invention relates to 2-thio-substituted imidazole derivatives of the formula I in which the radicals R 1 , R 2 R 3 and m are as defined in the description. The compounds according to the invention have immunomodulating and/or cytokine-release-inhibiting action and are therefore suitable for treating disorders associated with a disturbed immune system.

  本发明涉及公式I中的2-硫代取代咪唑衍生物，其中基团R1，R2，R3和m如描述中所定义。本发明的化合物具有免疫调节和/或细胞因子释放抑制作用，因此适用于治疗与免疫系统紊乱相关的疾病。
• Imidazole Inhibitors of Cytokine Release:  Probing Substituents in the 2 Position
  作者：Stefan A. Laufer、Hans-Günther Striegel、Gerd K. Wagner

  DOI：10.1021/jm020873z

  日期：2002.10.1

  Novel 2,4,5-trisubstituted imidazole derivatives were prepared as potential anticytokine agents. Thirty-seven compounds were tested on their ability to inhibit the release of tumor necrosis factor-a (TNF-alpha and interleukin-1beta (IL-beta) from peripheral blood mononuclear cells (PBMC) or human whole blood. SARs (structure activity relationships) for substituents-at the 4 and 5 position of the imidazole core were similar to those described for other inhibitors of cytokine. release and p38 MAP (mitogen-activated protein) kinase. Starting from benzylsulfanyl imidazole 2b (IC50 p(38), 4.0 muM; TNF-alpha, 1.1,muM; IL-1beta, 0.38,muM), the contribution of substituents at the 2 Position to enzyme inhibitory and cellular activity of test compounds was investigated. This strategy led to the identification of compound 2q (IC50 p38, 0.63 muM; TNF-alpha, 0.90 muM; IL-1beta, 0.04,muM), which was 6-10 times more potent than the initial lead 2b with respect to inhibition of p38 and IL-1beta release and equipotently inhibited TNF-alpha release.
• 2-ARYLALKYLTHIO -IMIDAZOLE, 2-ARYLALKENYL -THIO -IMIDAZOLE UND 2-ARYLALKINYL -THIO -IMIDAZOLE ALS ENTZÜNDUNGS -HEMMSTOFFE UND HEMMSTOFFE DER CYTOKIN -FREISETZUNG
  申请人：MERCKLE GMBH

  公开号：EP1112265A1

  公开（公告）日：2001-07-04
• US6432988B1
  申请人：——

  公开号：US6432988B1

  公开（公告）日：2002-08-13